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Background: Low 25-hydroxyvitamin D [25(OH)D] is associated with atherogenic dyslipidemia, diabetes mellitus, and metabolic syndrome. LDL-C 
estimated by Friedewald is less accurate in the metabolic syndrome. We studied lipid and lipoprotein characteristics associated with low 25(OH)D 
including directly measured “real” LDL (LDLr-C) and LDL modal density phenotype.
methods: 69,946 unique patients ≥18 years underwent clinically driven VAP II density gradient ultracentrifugation (Birmingham, AL) and 25(OH)
D (Diasorin RIA) testing during 2009 or 2010. We compared lipids and hsCRP across 25(OH)D quartiles and performed linear regression using log 
transformation of non-Gaussian distributed variables.
results: Lower 25(OH)D quartiles were associated with a higher prevalence of LDL pattern B (small dense LDL), with higher levels of non-HDL-C, 
TG/HDL-C ratio, IDL-C+VLDL3-C, LDLr-C, and hsCRP, and with lower HDL2-C and HDL3-C (Table). These associations remained in regression models 
adjusted for age and sex [p<0.001 for each of lower 3 25(OH)D quartiles compared to highest quartile, and for trend across quartiles.]
conclusion: In a large clinical sample with direct measurement of lipid subfractions, lower 25(OH)D levels are associated with a broad pattern of 
dyslipidemia, including abnormalities in LDLr-C, HDL-C subfractions, TG/HDL ratio (an index of insulin resistance), and remnant lipoproteins. Clinical 
trials are needed to determine whether treating low vitamin D can improve dyslipidemia. 
Quartiles of Serum 25-hydroxyvitamin D (ng/ml)
Quartile 1
N=17,481 (<21.3
Quartile 2
N=17,387 (≥21.3-
29)
Quartile 3
N=17,456 (≥29-
37.7)
Quartile 4
N=17,622 (≥37.7)
p
25(OH)D, ng/ml [range 4-150] 15.2±4.3 25.2±2.2 33.0±2.5 48.8±11.5
Age , years 56.6±15.3 57.7±15.1 59.2±14.9 61.1±14.8 <0.001
Women 58.9 52.8 54.3 58.2 <0.001
Total chol, mg/dl 200 ± 47 195 ± 44 189 ± 42 183 ± 42 <0.001
HDL-C, mg/dl 51 ± 16 52 ± 16 54 ± 17 57 ± 17 <0.001
HDL2-C, mg/dl 12 ± 6 12 ± 6 13 ± 7 14 ± 7 <0.001
HDL3-C, mg/dl 39 ± 10 40 ± 10 41 ± 11 43 ± 11 <0.001
LP(a)-C, mg/dl 7.9 ± 6 7.7 ± 6 7.8 ± 6 8.2 ± 6 <0.001
LDL-C, mg/dl 113 ± 47 113 ± 39 108 ± 36 103 ± 35 <0.001
LDLr-C, mg/dl 98 ± 36 96 ± 35 91 ± 33 86 ± 32 <0.001
LDL-pattern
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B
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<0.001
VLDL-C, mg/dl 29 ± 19 26 ± 13 24 ± 11 22 ± 9 <0.001
VLDL3-C, mg/dl 15 ± 7 14 ± 5 13 ± 5 12 ± 4 <0.001
Trig,*mg/dl 137 [94, 206] 128 [90, 185] 113 [81, 161] 100 [73, 140] <0.001
IDL-C, mg/dl 14 ± 8 13 ± 7 12 ± 6 11 ± 6 <0.001
IDL-C+VLDL3-C mg/dl 29 ± 14 27 ± 12 25 ± 10 23 ± 9 <0.001
Non-HDL-C, mg/dl 149 ± 46 143 ± 42 134 ± 39 126 ± 38 <0.001
TG/HDL-C ratio* 2.8 [1.7, 4.8] 2.6 [1.6, 4.2] 2.2 [1.3, 3.5] 1.8 [1.2, 2.9] <0.001
CRP,* mg/L 3.1 [1.4, 7.1] 2.3 [1, 5.2] 2 [0.9, 4.5] 1.7 [0.8, 4] <0.001
All variables in mean ± SD or % distribution unless noted. *median [IQR]
